Travere therapeutics initiates pivotal phase 3 clinical trial of pegtibatinase for the treatment of classical homocystinuria (hcu)

Potential for pegtibatinase to become first disease-modifying treatment for classical hcu; topline data expected in 2026 potential for pegtibatinase to become first disease-modifying treatment for classical hcu; topline data expected in 2026
TVTX Ratings Summary
TVTX Quant Ranking